| P50 | author | Hani Mawardi | Q64962185 |
| | Nadine Jackson McCleary | Q92628336 |
| P2093 | author name string | Alessandro Villa | |
| | Sook-Bin Woo | |
| | Nathaniel Treister | |
| | Peter Enzinger | |
| | Reshma Manon | |
| P2860 | cites work | Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. | Q43266784 |
| | Ziv-aflibercept: binding to more than VEGF-A--does more matter? | Q43816694 |
| | Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic | Q43968160 |
| | Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials. | Q51054919 |
| | Osteonecrosis of the jaw related to everolimus: a case report. | Q53313578 |
| | Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer. | Q53434420 |
| | Osteonecrosis of the jaw related to sunitinib. | Q54680163 |
| | American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update | Q56565081 |
| | Spontaneous alveolar bone sequestration. Case reports | Q73817753 |
| | Sunitinib related osteonecrosis of jaw: a case report | Q84323419 |
| | Incidence and management of ZIv-aflibercept related toxicities in colorectal cancer | Q26830219 |
| | Osteonecrosis of the jaw and use of bisphosphonates in adjuvant breast cancer treatment: a meta-analysis | Q33466845 |
| | Ziv-aflibercept use in metastatic colorectal cancer | Q33886059 |
| | Southwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer | Q34000985 |
| | Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases | Q35762495 |
| | Ziv-aflibercept in macular disease | Q35899591 |
| | Bisphosphonate and nonbisphosphonate-associated osteonecrosis of the jaw: a review | Q37538011 |
| | Physiology and pharmacology of nonbisphosphonate drugs implicated in osteonecrosis of the jaw. | Q38044141 |
| | An update on the pharmacotherapy of neovascular age-related macular degeneration. | Q38096462 |
| | Ziv-aflibercept: a novel angiogenesis inhibitor for the treatment of metastatic colorectal cancer | Q38152887 |
| | Epidemiology, clinical manifestations, risk reduction and treatment strategies of jaw osteonecrosis in cancer patients exposed to antiresorptive agents | Q38184580 |
| | Jaw osteonecrosis associated with aflibercept, irinotecan and fluorouracil: attention to oral district | Q38583014 |
| | Osteonecrosis of the jaw a new complication related to Ipilimumab. | Q38865775 |
| | VEGF secretion by neuroendocrine tumor cells is inhibited by octreotide and by inhibitors of the PI3K/AKT/mTOR pathway | Q39715131 |
| | Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture. | Q39928163 |
| | Osteonecrosis of the Jaw in the United States Food and Drug Administration's Adverse Event Reporting System (FAERS). | Q41470599 |
| | Osteonecrosis of the jaw related to everolimus and bisphosphonate: a unique case report? | Q42811436 |
| | Sunitinib may raise the risk of bisphosphonate-related osteonecrosis of the jaw: presentation of three cases | Q42943770 |
| | Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer | Q43111250 |
| P433 | issue | 6 | |
| P921 | main subject | aflibercept | Q4689286 |
| P304 | page(s) | E81-E87 | |
| P577 | publication date | 2016-12-01 | |
| P1433 | published in | Journal of gastrointestinal oncology | Q26842467 |
| P1476 | title | Osteonecrosis of the jaw associated with ziv-aflibercept | |
| P478 | volume | 7 | |